| Vancomycin (n = 7) | Daptomycin (n = 7) | All (n = 14) |
---|
Serious adverse eventsa | 4 | 3 | 7 |
Adverse events | | | |
Cardiac arrhythmia | 2 | 1 | 3 |
General cardiacb | 2 | 1 | 3 |
Constitutional symptomsc | 0 | 2 | 2 |
Dermatologicd | 3 | 0 | 3 |
Adrenal insufficiency | 0 | 1 | 1 |
Eosinophilia | 0 | 1 | 1 |
Fall | 1 | 1 | 2 |
Nausea and vomiting | 0 | 1 | 1 |
Anemia | 1 | 1 | 2 |
Infectione | 3 | 4 | 7 |
Neurologicalf | 2 | 1 | 3 |
Pain | 2 | 1 | 3 |
Hematuria | 0 | 1 | 1 |
- Data are number of cases
- aIn the vancomycin arm this included intracranial hemorrhage, catheter-related infection, acute coronary syndrome and vascular access complication. In the daptomycin arm this included catheter-related infection and hypotension
- bIncluding adverse events termed “acute coronary event”, “hypotension”, and “pulmonary edema”
- cIncluding events termed “somnolence” and “fever”
- dIncluding events termed “rash-maculopapular” and “pruritus”
- eIncluding events termed “catheter-related infection” and “urinary tract infection”
- fIncluding events termed “seizure”, “intracranial hemorrhage”, and “dizziness”